<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453504</url>
  </required_header>
  <id_info>
    <org_study_id>HD-R3i</org_study_id>
    <nct_id>NCT01453504</nct_id>
  </id_info>
  <brief_title>Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma</brief_title>
  <acronym>HD-R3i</acronym>
  <official_title>A Prospective, Randomized, Placebo-controlled, Multicenter, International Phase I/II Trial of RAD001 (Everolimus) in Combination With DHAP as Induction Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is

        1. to determine the recommended dose of everolimus for a subsequent Phase II trial

        2. to determine the efficacy of everolimus plus DHAP
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity Rate (DLT)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Phase I primary outcome measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Remission Rate (CR)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Phase II primary outcome measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>Phase I secondary outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor status (assessed by CT) after chemotherapy</measure>
    <time_frame>4 weeks</time_frame>
    <description>Phase II secondary outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor status (assessed by PET) after chemotherapy</measure>
    <time_frame>4 weeks</time_frame>
    <description>Phase II secondary outcome measure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Ever-DHAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination of Everolimus and DHAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-DHAP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHAP</intervention_name>
    <description>Dexamethasone, Cytarabine, Cisplatin</description>
    <arm_group_label>Ever-DHAP</arm_group_label>
    <arm_group_label>Placebo-DHAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>Ever-DHAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  relapsed or refractory Hodgkin Lymphoma

          -  age 18-60

          -  histology confirmed relapse

        Exclusion Criteria:

          -  previous therapy with mTOR inhibitor

          -  current CNS involvement

          -  other primary malignant disease within the last 3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Borchmann, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Cologne, German Hodgkin Study Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Fuchs</last_name>
    <email>ghsg@uk-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>1st Dept. of Medicine, Cologne University Hospital</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Fuchs</last_name>
      <email>ghsg@uk-koeln.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ghsg.org</url>
    <description>Homepage GHSG</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2011</study_first_submitted>
  <study_first_submitted_qc>October 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2011</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Peter Borchmann</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

